Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PinnacleXon Feb 28, 2022 6:36pm
160 Views
Post# 34469392

RE:RE:RE:RE:RE:RE:Nothing changes

RE:RE:RE:RE:RE:RE:Nothing changes
SPCEO1 wrote: I absolutely want a CEO who sells a dream that is logical and can be achieved. I want him selling that as much as possible to investors as that is what investors respond to. And TH has just such a dream but TH has never been able to sell it effectively, even to a market that was crazy enough to buy into the lunatic dreams of CYDY among many, many others. Those crazy times have passed for now, however, so TH will need to work even harder to get investor attention. And while I have said it many times, I just don't think you can accept it, but a stock price is pushed up by investors who are anticipating good things to come just as much as, if not more, than it is by those good things actually happening. You may recall that  TH's stock price rose considerably more percentage-wise before Trogarzo was approved than it did after. 

No reasonable investor wants the company to be selling stuff it does not have a reasonable chance to deliver on. TH itself and you often raise that as a defense of your position but no one here is asking them to become CYDY. So, please do your best to drop that line of thinking as no one is actually asking for that.

The TH stock price will rise once inestors are sold the story that they can make a lot of money on the stock if the company can execute on its business plan, which is well before it actually does execute on its business plan. Because TH has failed to execute on its first two attempts  and also because the phase 1a has gone on longer than expected, they will undoubtedly have a more difficult time convincing investors they can successfully execute their plans for cancer or NASH, But I suspect those attitudes could be close to changing as things start to fall into place.

jfm1330 wrote: I still don't understand the thinking that lead you to think that a CEO can push the SP up without any meaninful achievement by the company he is leading. The last time Thera's SP went up significantly is after Trogarzo's approval. It was a mirage becauses sales never followed, but still, it was a significant achievement. If the CEO you want is a dream seller, say it clearly. Tanguay was too serious to do that, and Levesque, even though not as grumpy, will not promise miracles.

I am not unhappy because they are not pushing BS enough, I am unhappy because they are not executing well on the timelines they told us they would achieve. If there is something, Levesque promised too much on NASH, and did not delivered. I am happy he did not, but still, the company was supposed to go in phase III alone and so on. Now it's the same with TH1902. They were bragging almost a year ago that they started the phase Ia ahead of schedule, but now they are way behind their own schedule with no explainations to justify it. 

The SP will rise if they can finally come up with a real good news, something really significant. A 28 years old biotech that never made money will not rise on promises. They need to finally deliver.


SPCEO1 wrote: Are you happy with the stock price since Paul took over?

palinc2000 wrote:

Someone gave you a thumbs up for your post in which you mention that we may need a new CEO
?????? Gees!!!

 

SPCEO1 wrote: Given that the bubble has been popped, retain investors have been hammered and the bull market is gone too, the chances of a really good stock price response to any positive information TH might report in the weeks ahead is far less than it once was. Since TH still has no effective research coverage and has yet to hire a IR person (I am sure all noticed an LSA was the MC on the conference call), it is not clear to me how the stock will get the sponsorship it needs to move significantly higher on good news. The trading volume recently has been totally dreadful as well as it is clear few other than ourselves are paying much attention to TH. Our CEO has done a lot of positive things but he has not even come close to fixing these issues with the marketing of the stock and the environment to now do so is much more difficult than it was through most of his now nearly 2 year tenure. From my perspective, it is a really big failure. He has given us the ONO, lower analyst coverage, lower trading volume and no sponsorship of the stock - if the Grumpy Grader came out from hibernation the only grade he could possibly give would be an F-. Since we are the people our CEO actually works for, it is hard to understand how this has not been a higher priority for him to get sorted out. And the board member added to appease grumpy shareholders has also not shown to be able to convince Paul of doing things more successfully either. Since Paul joined TH, the stock price has gone nowhere even though he has significantly improved the prospects of the company. In the end, if the stock price does not reflect the improvement, we may need a new CEO who has a better grasp on tying improving trends at the company to improving trends in the stock price.

The defense the company gives is that TH has greatly outperformed the XBI over the last year. Unfortunately, we cannot eat relative performance - we need the stock price to actually rise.  
 

 

Bucknelly21 wrote: Despite learning many valuable lessons from the market and some analysts thera continues on the same non effective path in regards to transparency and market engagement. Do we really think that even if they get good results from the 1a/b that they will be able to capture the appreciation that would be due? Idk even if a Chinese partnership is announced they have not shown me they are capable of doing a good deal. I hope im wrong but im just going off past experience 

 

 

 

 




 Funny how you ask him to drop his line of thinking, its you that should, and apologize to all your investors for being a naive, stubborn little man.  Same thing everyday from the same people here talking like they know better, but at the end of the day SP tells all.  
<< Previous
Bullboard Posts
Next >>